BofA lowered the firm’s price target on Novo Nordisk (NVO) to DKK 315 from DKK 375 and keeps a Neutral rating on the shares. The firm, which assumes a reported decline of about 5% in sales and about 7% in EPS in FY26, notes that its FY26 sales and EPS views are about 10% below consensus, though the latter is “updating rapidly” following the company’s “tough” FY26 guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. The Next Big Pharma Target?
- Video: Health insurers weighed on by shutdown news, Trump post
- Morning Movers: Monday.com sinks following third quarter results
- Novo Nordisk Stock (NVO) Rises on Plan to Pursue Other Obesity Deals after Metsera Loss
- Novo continues to look for opportunities in obesity, diabetes, Bloomberg says